In addition to attempting to inhibit SHH signaling—a strategy that can be foiled by the development of secondary mutations (Yauch et al., 2009)—we hypothesized that controlling the levels of Atoh1 protein will provide another therapeutic entry point for the treatment SHH-driven medulloblastoma. The gene discussed is SHH; the disease is medulloblastoma.